Trial Profile
Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Sep 2007
Price :
$35
*
At a glance
- Drugs MTC DOX (Primary) ; Doxorubicin; Doxorubicin
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors FeRx
- 13 Sep 2007 New trial record.